NCT06595758 is a clinical trial in Breast Cancer, sponsored by Menoufia University.

Who is sponsoring NCT06595758?

NCT06595758 is sponsored by Menoufia University.

What condition does NCT06595758 study?

NCT06595758 studies Breast Cancer.

Is NCT06595758 still recruiting?

NCT06595758 is currently completed. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT06595758

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

This Study Investigates the Impact of Single Nucleotide Polymorphisms in Genes Involved in the Pharmacokinetics and Toxicity of Doxorubicin (DOX) in Egyptian Female Patients with Breast Cancer. It Also Aims to Explore the Association of Pretreatment Neutrophil to Lymphocyte Ratio to PCR

Completed Last updated 19 September 2024

What this trial tests

trial in Breast Cancer in 100 participants. Completed in 1 November 2023.

Timeline

1 October 2021

Primary endpoint
1 November 2022

1 November 2023

Quick facts

Lead sponsor	Menoufia University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 October 2021
Primary completion	1 November 2022
Estimated completion	1 November 2023
Sites	1 location across Egypt

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Menoufia University

Who can join

Adults 18 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the effect of single nucleotide polymorphisms (SNPs) of genes involved in doxorubicin transport and metabolism on its pharmacokinetics and toxicity in Egyptian breast cancer patients. It also aims to explore the association of pretreatment neutrophil to lymphocyte ratio (NLR) with pathological complete response (pCR).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Is the Neutrophil-to-Lymphocyte Ratio a Predictive Factor of Pathological Complete Response in Egyptian Breast Cancer Patients Treated with Neoadjuvant Chemotherapy?
Ebaid NF, Abdelkawy KS, Said ASA, Al-Ahmad MM, et al · · 2025 · PMID 40005444 · DOI 10.3390/medicina61020327

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Menoufia University trials

Trials by the same sponsor.

NCT07522671 — Clinical Performance of 3D-Printed Resin and Zirconia Implant Restorations · NA · recruiting
NCT07516236 — Dynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock · not yet recruiting
NCT07485517 — Deep Versus Moderate Neuromuscular Blocking · NA · recruiting
NCT07506044 — Dexmedetomidine as an Adjuvant During Dural Puncture Epidural · NA · recruiting
NCT07322471 — Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06595758 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Menoufia University
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06595758.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing